Ligand assisted CuAAC labelling and RP-HPLC analysis of zidovudine and Retrovir using propargyl-Fmoc probe.

This study focuses on ligand assisted cuaac labelling and rp-hplc analysis of zidovudine and retrovir using propargyl-fmoc probe.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the pharmaceutical field. The extensive application of zidovudine (ZDV) as a stand-alone anti-HIV drug and a component in antiviral combination therapies, has made its analysis important both in the pharmaceutical and environmental context. The azide group in ZDV structure makes it a ready-to-use substrate for copper-catalyzed azide-alkyne cycloaddition (CuAAC), which is an efficient... Research Background and Significance Zidovudine (ZDV), also known under the brand name Retrovir, is a nucleoside reverse transcriptase inhibitor widely used in the treatment of HIV infection. Its importance extends beyond clinical therapy to environmental and pharmaceutical analytical settings due to its prevalent use and potential residues. ZDV's molecular structure includes an azide functional group, which presents unique opportunities for selective chemical modification and detection. Copper-catalyzed azide-alkyne cycloaddition (CuAAC), often referred to as 'click chemistry,' is a highly efficient and selective reaction that has been harnessed to label azide-containing molecules. The ligand-assisted CuAAC approach enhances reaction rates and selectivity, providing a robust platform for tagging ZDV with a propargyl-Fmoc probe. This labelling facilitates subsequent chromatographic detection and quantification. The current study addresses the analytical challenges in accurately quantifying ZDV and its formulations by developing and validating a reversed-phase high-performance liquid chromatography (RP-HPLC) method coupled with this innovative chem